
Opinion|Videos|July 29, 2024
Decision-Making in CLL: The Role of Real-World Evidence
A discussion on therapeutic decision-making in CLL and the role of real-world evidence.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How do you integrate real-world evidence into your clinical decision-making process for BTK inhibitors in CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5













































